Abstract：
Metformin appears to reduce TSH levels in untreated hypothyroid patients. In contrast, in euthyroid patients with type 2 diabetes mellitus (T2DM), metformin is initially devoid of effects on TSH. However, it is followed by a significant reduction in TSH level after twelve months of treatment. Additionally, some evidence suggests that metformin may also improve thyroid morphological abnormalities. This study aimed to evaluate the effects of metformin not only on TSH and thyroid hormone values, but also on thyroid volume and nodules. A total of 50 patients (mean age: 36.9 ± 12.8 years) with insulin resistance (homeostatic model assessment (HOMA) index ≥2.5) and with thyroid uninodular disease were recruited for this study. They were prescribed slow-acting metformin at a daily dose of 500 mg for six months. Treatment with metformin in euthyroid patients with uninodular thyroid disease and insulin resistance reduces TSH levels, increases FT4 and FT3 values, and decreases thyroid and nodule volumes. These data suggest that metformin may be an effective drug not only for the treatment of T2DM and metabolic syndrome, but also for thyroid disease.
摘要：
二甲双胍似乎可降低未经治疗的甲状腺功能减退患者的TSH水平。相比之下,在2型糖尿病（T2DM）的甲状腺功能正常患者中，二甲双胍最初对TSH没有影响。然而,治疗12个月后TSH水平显著下降.此外,一些证据表明二甲双胍也可以改善甲状腺形态异常.这项研究旨在评估二甲双胍不仅对TSH和甲状腺激素值的影响，还有甲状腺体积和结节。本研究共招募了50名患有胰岛素抵抗（稳态模型评估（HOMA）指数≥2.5）和甲状腺单结节性疾病的患者（平均年龄：36.9±12.8岁）。他们每天服用500毫克的缓效二甲双胍，持续6个月。二甲双胍治疗甲状腺功能正常的单结型甲状腺疾病和胰岛素抵抗患者可降低TSH水平，增加FT4和FT3值，减少甲状腺和结节体积。这些数据表明，二甲双胍可能不仅是治疗T2DM和代谢综合征的有效药物。还有甲状腺疾病。
